Search

Your search keyword '"Tsai, Sheng-Ta"' showing total 23 results
Start Over Author "Tsai, Sheng-Ta" Publication Year Range Last 10 years
23 results on '"Tsai, Sheng-Ta"'

14. Use of a Smartphone Application to Speed Up Interhospital Transfer of Acute Ischemic Stroke Patients for Thrombectomy

Author

Tsai, Sheng-Ta, primary, Wang, Wei-Chun, additional, Lin, Yu-Ting, additional, Huang, Wei-Shih, additional, Huang, Hung-Yu, additional, Wang, Chun-Ju, additional, Lin, En-Zu, additional, Kung, Wei-Ling, additional, Guo, Yuh-Cherng, additional, Lin, Kang-Hsu, additional, Lu, Ming-Kuei, additional, Yen, Pao-Sheng, additional, Chen, Wei-Laing, additional, Tseng, Ying-Lin, additional, Kuo, Chin-Chi, additional, Cho, Der-Yang, additional, Chen, Chun-Chung, additional, and Tsai, Chon-Haw, additional

Published
2021
Full Text
View/download PDF

22. Transient receptor potential V1 modulates neuroinflammation in Parkinson's disease dementia: Molecular implications for electroacupuncture and rivastigmine.

Author

Tsai ST, Wei TH, Yang YW, Lu MK, San S, Tsai CH, and Lin YW

Abstract

Objectives: Parkinson's disease (PD) is a common progressive neurodegeneration disease. Its incidence increases with age and affects about 1% of people over 60. Incidentally, transient receptor potential V1 (TRPV1) and its relation with neuroinflammation in mouse brain has been widely reported., Materials and Methods: We used 6-hydroxydopamine (6-OHDA) to induce PDD in mice. We then used the Morris water maze and Bio-Plex to test learning and inflammatory mediators in mouse plasma. Western blotting and immunostaining were used to examine TRPV1 pathway in the hippocampus and medial prefrontal cortex (mPFC)., Results: On acquisition days 3 (Control = 4.40 ± 0.8 sec, PDD = 9.82 ± 1.52 sec, EA = 5.04 ± 0.58 sec, Riva = 4.75 ± 0.87 sec; P =0.001) and 4, reversal learning days 1, 2, 3 (Control = 2.86 ± 0.46 sec, PDD = 9.80 ± 1.83 sec, EA = 4.6 ± 0.82 sec, Riva = 4.6 ± 1.03 sec; P =0.001) and 4, PDD mice showed significantly longer escape latency than the other three groups. Results showed that several cytokines were up-regulated in PDD mice and reversed by EA and rivastigmine. TRPV1 and downstream molecules were up-regulated in PDD mice and further reversed by EA and rivastigmine. Interestingly, α7 nicotinic receptors and parvalbumin levels in both the hippocampus and prefrontal cortex increased in EA-treated mice, but not in rivastigmine-treated mice., Conclusion: Our results showed that TRPV1 played a role in the modulation of neuroinflammation of PDD, and could potentially be a new target for treatment., Competing Interests: The authors declare no conflicts of interest.

Published
2021
Full Text
View/download PDF

23. Immunoglobulin G4-Related Disease Presented as Recurrent Otitis Media and Mixed Hearing Loss Treated With Cyclophosphamide and Rituximab: A Case Report.

Author

San S, Lin CD, Tsai ST, Lin CC, and Wu PC

Abstract

Immunoglobulin G4-related disease (IgG4-RD) is a systemic autoimmune disease; however, it rarely presents as recurrent otitis media and mixed hearing loss. In this article, we present a 43-year-old male patient who presented with recurrent otitis media and mixed hearing loss that is the 12th case of IgG4-RD with middle and inner ear involvement. We also report the clinical response of cyclophosphamide and rituximab therapy in IgG4- RD. These two drugs have never been used to treat otologic symptoms, but were used to treat other organs affected by IgG4-RD. One year later, the patient underwent mastoidectomy of the right ear and the pathological reports revealed IgG4-related disease. A rheumatologist administered immunosuppressive therapy comprising cyclophosphamide and rituximab. After therapy, patient's right-sided mixed hearing loss partially improved. We recorded all pure tone audiometry data to evaluate the clinical course and treatment effect. Finally, we concluded that pathological confirmation and further immunosuppressive therapy should be considered in a timely manner to prevent hearing impairment. We recommend cyclophosphamide and rituximab for the treatment of diseases involving the middle and inner ear., Competing Interests: Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results